Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
|Videos|March 3, 2015
How Health Information Technology has Changed the Business of Pharmacy
Ludy L. Underwood, Cardinal Health sales manager for retail/alternative care, pharmaceutical division, talks about how health information technology has changed the business of pharmacy.
Advertisement
Ludy L. Underwood, Cardinal Health sales manager for retail/alternative care, pharmaceutical division, talks about how health information technology has changed the business of pharmacy.
This interview was recorded at the Pharmacy Development Services 2015 conference in Orlando, Florida.
Advertisement
Related to this article
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
4
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
5